2026 Agenda

FIRESIDE CHAT:
Sponsored by: Transforming Clinical Trials with a Patient-Derived Foundational AI Model

Billions of dollars are invested into pre-clinical drug discovery, yet the promise of AI falls short in clinical trials which results in a $1B dollar bottleneck and 7 + years in development. This fireside chat will address the challenge and how one company is transforming clinical trials with a proprietary patient-driven AI model.

Sponsored by: Vivo: The Real-Time AI Control Tower for Clinical Trial Execution

An overview of OmniScience’s Vivo and its real-time AI control tower, showing how unified and AI-ready trial data and proactive intelligence improve execution, speed, and decision-making in clinical operations.

Sponsored by: Point-of-Care Research Enablement Layer

Trial IQ aims to enable underutilized community practices and infusion centers to become research-ready and connect them into a support network that expands patient access. Early partners are sought to help define site readiness, partnership approaches, and integration standards.

Sponsored by: World Models Accelerating Clinical Trials 

Clinical trials remain slow, costly, and failure-prone due to protocol design flaws, data scarcity, and limited ability to test decisions before execution. This presentation introduces clinical world models, a new class of generative AI that learn disease dynamics and simulate how patient journeys evolve over time. Ari Yacobi will outline the core architecture, share results from disease-specific pilots generating high-fidelity synthetic patient trajectories, and discuss how this approach enables earlier decision-making, reduces risk, and accelerates clinical development.

Sponsored by: Venture Capital's Role in Propelling Clinical Trials Forward

Venture capital is playing an increasingly critical role in accelerating oncology innovation by reshaping how early-stage clinical trials are financed, designed, and executed. In this presentation, Cancer Focus Fund outlines its vision to finance, design, and administer more than 100 Phase I/II clinical trials over the next decade, leveraging the clinical trial expertise of MD Anderson Cancer Center. Attendees will gain insight into how this model bridges scientific discovery and commercialization, creating value for investors while bringing best-in-class cancer therapies to patients faster and more efficiently.